TORONTO, July 21 /CNW/ - The Centre for ADHD/ADD Advocacy, Canada
(CADDAC) applauds the Saskatchewan Ministry of Health for its decision to
provide access to long-acting ADHD medications with the listing of Concerta
and Strattera in the province's drug formulary.
"We congratulate the Province of Saskatchewan and the Honourable Don
McMorris, Minister of Health, for taking the lead by making this important
decision to support academic achievement and workplace success in time to have
impact on the next school year," said Heidi Bernhardt, National Director of
CADDAC. "We will be calling on your colleagues in other provinces to follow
The use of long-acting medications work better for patients as they
provide a smooth and sustained effect, have less potential for abuse and avoid
the stigmatization that can occur when children and youth must take ADHD
medications during school hours.
"There is no 'one size fits all' when it comes to the treatment of ADHD
and the patient's clinical and social profile need to be taken into account
when choosing the right drug," said Bernhardt. "By providing coverage of
Concerta and Strattera physicians in Saskatchewan can now prescribe
long-acting mediations for patients without private insurance."
ADHD affects approximately five to 12 per cent of all school-age
children. Although many people tend to think of ADHD as a childhood problem,
up to 66 per cent of children still exhibit symptoms into adulthood. It is
considered one of the most commonly diagnosed neurological disorders among
"We realize that drug funding decisions are complex and believe that real
world issues beyond simply clinical trial data must also be taken into
consideration. We commend the government of Saskatchewan for also recognizing
that longer-acting medications mean fewer pills and that fewer pills decrease
the risk of abuse," added CADDAC Board Director, Dianne Azzarello.
"Many of the common symptoms of ADHD, inattention, disorganization, poor
impulse control, losing things and forgetfulness, make it extremely difficult
for children and adults with ADHD to consistently take medication three times
a day at regular hours," said Azzarello. "Expecting schools to take on the
role of medical care providers and dispense controlled medication safely and
consistently is unrealistic and results in ineffective treatment for this
highly treatable condition. CADDAC encourages each of the provinces to invest
in providing access to all once-a-day medications."
CADDAC is a not-for-profit organization that provides leadership in
education and advocacy for ADHD organizations and individuals with ADHD across
Canada. CADDAC provides a wide-range of information for children, parents,
doctors and educators on their website www.caddac.ca.
For further information:
For further information: or to arrange interviews with parents, children
or doctors, please contact: Heidi Bernhardt, National Director, CADDAC, (416)
637-8584, email@example.com; or Jane Hamilton at (905) 466-2070,